Share
- Release Date: 10/07/13 15:50
- Summary: DIRECTOR: PEB: Appointment of Independent Director
- Price Sensitive: No
- Download Document 2.14KB
PEB
10/07/2013 13:50
DIRECTOR
REL: 1350 HRS Pacific Edge Limited
DIRECTOR: PEB: Appointment of Independent Director
10 July 2013
Bryan Williams FRSNZ, FAA, who has a distinguished career in cancer research
and international business, has accepted appointment to the Board of Pacific
Edge Limited as an Independent Director.
Dr Williams is the former Chairman of Sydney-based Marshall Edwards Pty Ltd
(now Nasdaq-listed MEI Pharma), which specialises in the clinical development
of novel therapies for cancer. In his capacity as Chairman, he negotiated
licensing deals with major pharmaceutical companies, oversaw two capital
raisings totalling $40 million and the transfer of the company from Sydney to
San Diego. Dr Williams retired from the Board last year.
His previous experience includes raising the initial venture capital for
Gemini Technologies in the United States, a business based on scientific
research at the Lerner Institute, and positions as Scientific Advisor to
other life science start-ups. He was a co-founder of Alios BioPharma in the
United States which licensed patents held by him and others.
Born and educated in New Zealand, Dr Williams became one of America's
accomplished cancer experts specialising in molecular biology of tumour
suppression. He is internationally recognised for his contributions to
research on Wilms Tumor, a cancer of the kidney that primarily affects
children, and for studies on protein kinase R, an important cellular
signalling molecule. Currently, Dr Williams is Director of the Monash Medical
Institute in Melbourne. Dr Williams is an Honorary Fellow of the Royal
Society of New Zealand and a Fellow of the Australian Academy of Science.
Pacific Edge Chairman, Chris Swann, says Pacific Edge will benefit greatly
from Bryan Williams's US commercial experience and his international cancer
standing.
"As an acknowledged leader in cancer research and with extensive experience
in leading life science companies and commercial evaluation of technologies,
Dr Williams will provide a great complement to the skills and capabilities of
the existing Board members."
End CA:00238430 For:PEB Type:DIRECTOR Time:2013-07-10 13:50:11
